Clinical Trial Update: A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial protocol investigates a post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis approach in patients with hemat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Lymphoma
• Myelodysplastic Syndrome
• Myelogenous Leukemia
• Myelomonocytic Leukemia
• Prolymphocytic Leukemia

Drugs mentioned

• Cyclophosphamide (Cytoxan) (cyclophosphamide)

Snippet

Sponsor: Center for International Blood and Marrow Transplant Research | Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | Phase 2 | Status: RECRUITING